James E. Goldschmidt
Corporate Officer/Principal bei CASI PHARMACEUTICALS, INC.
Profil
James E.
Goldschmidt is currently the President-United States at Sandoz, Inc. and the Chief Business Development Officer at CASI Pharmaceuticals, Inc. Previously, he held positions such as Executive Director-Business Development at Johnson & Johnson, Executive Director-Oncology New Business at Wyeth Pharmaceuticals LLC, Product Director at GSK Plc, and Senior Vice President-Business Development at CASI Pharmaceuticals, Inc. He also served as the Vice President-Business & Commercial Development at TetraLogic Pharmaceuticals Corp., Vice President-Business Development at ImmuneXcite, Inc., and Chief Operating Officer at Macrophage Therapeutics, Inc. Dr. Goldschmidt obtained a graduate degree from Drexel University, an undergraduate degree from Villanova University, and a doctorate degree from Temple University School of Medicine.
Aktive Positionen von James E. Goldschmidt
| Unternehmen | Position | Beginn |
|---|---|---|
| CASI PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.04.2016 |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von James E. Goldschmidt
| Unternehmen | Position | Ende |
|---|---|---|
Macrophage Therapeutics, Inc.
 Macrophage Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Navidea Biopharmaceuticals, Inc., Macrophage Therapeutics, Inc. develops immune-oncology and anti-inflammatory therapeutics. The CEO of the American company is Mike M. Goldberg. | Chief Operating Officer | 01.03.2016 |
ImmuneXcite, Inc.
 ImmuneXcite, Inc. Pharmaceuticals: MajorHealth Technology ImmuneXcite, Inc. operates as a biopharmaceutical company which develops monoclonal antibodies for cancer. The firm provides nivel immuno-incology technology platform, which leverages both the innate and adaptive immune responses to selectively treat a wide range of tumor types. The company was Ifat Rubin-Bejerano, Gerald R. Fink and Yaniv Bejerano and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01.01.2015 |
| TETRALOGIC PHARMACEUTICALS CORPORATION | Investor Relations Contact | 01.01.2013 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Corporate Officer/Principal | 01.01.2004 |
Ausbildung von James E. Goldschmidt
| Drexel University | Graduate Degree |
| Villanova University | Undergraduate Degree |
| Temple University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| TETRALOGIC PHARMACEUTICALS CORPORATION | Health Technology |
| GSK PLC | Health Technology |
| CASI PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
CASI Pharmaceuticals, Inc. /Old/
 CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD. | Health Technology |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Health Technology |
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
ImmuneXcite, Inc.
ImmuneXcite, Inc. Pharmaceuticals: MajorHealth Technology ImmuneXcite, Inc. operates as a biopharmaceutical company which develops monoclonal antibodies for cancer. The firm provides nivel immuno-incology technology platform, which leverages both the innate and adaptive immune responses to selectively treat a wide range of tumor types. The company was Ifat Rubin-Bejerano, Gerald R. Fink and Yaniv Bejerano and is headquartered in Waltham, MA. | Health Technology |
Macrophage Therapeutics, Inc.
Macrophage Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Navidea Biopharmaceuticals, Inc., Macrophage Therapeutics, Inc. develops immune-oncology and anti-inflammatory therapeutics. The CEO of the American company is Mike M. Goldberg. | Commercial Services |
